FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Print or Ty	pe Response	s)												
1. Name and Address of Reporting Person* Barnett Eva Renee				2. Issuer Name and Ticker or Trading Symbol Immunovant, Inc. [IMVT]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) (Middle) C/O IMMUNOVANT, INC., 320 W 37TH STREET, 6TH FLOOR				3. Date of Earliest Transaction (Month/Day/Year) 01/07/2022						X Officer (give title below) Other (specify below) Chief Financial Officer				
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person				
NEW YORK, NY 10018 (City) (State) (Zip)				Table I - Non-Derivative Securities Acqu						ived Disposed of an Panaficially Owned				
1 7141 - 60		` ′	2 T		_		1							7 N-+
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)		Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)			6. Ownership Form:	Beneficial
			(Month/Day/Year)	Code	V	Amount	(A) or (D)	Price	(Instr. 3 a	and 4)		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)	
Common	Stock (1)		01/07/2022		S		29,959	D	\$ 7.25	172,541			D	
				Derivative Securit	ies Acquir	the f	orm disposed of	plays a f, or Ben	currer reficiall	ntly valid		spond unle trol number		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Da	4. Transaction Code (Instr. 8)	if Transaction Number and Code of (M		Date Exercisable d Expiration Date Am Ionth/Day/Year) Und Sec			Title and nount of derlying curities str. 3 and			Ownershi Form of Derivativ Security: Direct (D or Indirect	Ownership (Instr. 4) ct
				Code V	(A) (D)	Date Exer		Expiration Date	Title	Amount or Number of Shares				
Repor	ting O	wners												
				Relati	ionships									
Reno	rting Owner	· Name / Addre	988	100/										

Signatures

Barnett Eva Renee

C/O IMMUNOVANT, INC.

NEW YORK, NY 10018

320 W 37TH STREET, 6TH FLOOR

/s/ Eva Renee Barnett	01/11/2022
**Signature of Reporting Person	Date

Director

Owner

Officer

Chief Financial Officer

Other

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- On October 4, 2021, the holder was granted 59,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on October 5, 2021. These RSUs vested in their (1) entirety on January 1, 2022. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of these RSUs.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.